KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

NCT06099821 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Digestive System Cancers

Interventions

DRUG: KN046
DRUG: Regorafenib
DRUG: Apatinib

Sponsor

Peking University Cancer Hospital & Institute